CLOs on the Move

LAVA Therapeutics

www.lavatherapeutics.com

 
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Amy Garabedian
General Counsel and Corporate Secretary Profile

Similar Companies

Ventus Therapeutics

Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases.

Bioscience

Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Arsanis Inc

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.

Odyssey Thera FKA: Odyssey Pharmaceuticals

Odyssey Thera FKA: Odyssey Pharmaceuticals is a San Ramon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Urigen Pharmaceuticals

Urigen Pharmaceuticals is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.